Saurabh Saha

Saha received his undergraduate degree in biology from the California Institute of Technology.^[2] He also attended both Harvard Business School and Oxford University.^[3] Saha trained under Bert Vogelstein during his studies at the Johns Hopkins School of Medicine,^[4] where he received both an MD and a PhD in cancer genetics.^[5]

After finishing graduate school, Saha joined the management consulting firm McKinsey & Company in their Pharmaceuticals and Medical Products Practice in New York City.^[6] In 2005, he became the Director of the New Indications Discovery Unit at the Novartis Institutes for BioMedical Research based in Cambridge, Massachusetts.^[5] Between 2008 and 2015, Saha served as the President of BioMed Valley Discoveries^[7][3] Saha serves as a venture partner for the life sciences venture capital firm, Atlas Venture and also served as the Chief Medical Officer for its portfolio company, Synlogic.^[8]

In 2016, Saha was appointed as President and CEO of Delinia, a biotech company focused on developing novel therapies for the treatment of cancer and autoimmune diseases such as lupus, inflammatory bowel disease, rheumatoid arthritis and others.^[9][10][11]

Saha has published in periodicals where he and his colleagues reported translational research and development discoveries in cancer research.^{[12][13][14][15][16][17][18]} He is also on the editorial boards of the American Journal of Clinical Oncology,^[19] Journal of Translational Medicine,^[20] and Cancer Biology & Therapy.^[21]